Back to top
more

Pieris Pharmaceuticals (PIRS)

(Delayed Data from NSDQ)

$11.16 USD

11.16
2,144

+0.02 (0.18%)

Updated May 9, 2024 03:27 PM ET

After-Market: $11.29 +0.13 (1.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PIRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Pieris Pharmaceuticals, Inc. [PIRS]

Reports for Purchase

Showing records 21 - 40 ( 91 total )

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

01/27/2020

Company Report

Pages: 9

Chess Move Not Surprising; Year of Focus for ''060 and ''343; Target Increased to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

01/17/2020

Daily Note

Pages: 3

Dropping Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

11/20/2019

Company Report

Pages: 9

KOL Day Shines Important Spotlight on PRS-060 and the New Excitement Around PRS-343

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

11/11/2019

Company Report

Pages: 7

3Q19 Results; Project Significant Boost in Pieris Visibility Over Near Term

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

11/11/2019

Company Report

Pages: 10

Welcome Back ‘343; First Look at SITC Reignites I-O Franchise

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

11/05/2019

Daily Note

Pages: 4

First Real Look at PRS-343 Data Should Reignite Interest

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

10/01/2019

Company Report

Pages: 7

PRS-060 Ready for Next Steps; Discussions With AstraZeneca Move Forward in Earnest

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

09/27/2019

Company Report

Pages: 7

PRS-060 Continues Delivering Positive Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

09/23/2019

Company Report

Pages: 6

PRS-060 Continues Its Push Forward as Signals Remain Positive

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

08/01/2019

Company Report

Pages: 6

Eyes on Important Data Inflection Points in 2H19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

06/17/2019

Daily Note

Pages: 5

PRS-080 Decision Now In the Hands of ASKA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

05/23/2019

Daily Note

Pages: 7

First-In-Human PRS-060 Data Presented Setting Stage for Positive Future

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

05/23/2019

Daily Note

Pages: 7

First-In-Human PRS-060 Data Presented Setting Stage for Positive Future

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

03/19/2019

Company Report

Pages: 6

2018 Results; Upcoming Key Data in Both Respiratory and Oncology Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

11/07/2018

Company Report

Pages: 7

3Q18 Results; Show Me Stage Increases on Promising Pipeline; Target Reduced to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

09/04/2018

Daily Note

Pages: 6

''343 Program Expands as Expected; Important Data Catalysts by Year End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

08/09/2018

Company Report

Pages: 6

2Q18 Results; Driving Toward Inflection Points for Lead Assets; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

06/07/2018

Company Report

Pages: 5

Progress Update on Enrollment and Tumor Types for PRS-343 Ahead of 2H18 Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

05/10/2018

Company Report

Pages: 6

1Q18 Results; Upcoming PRS-343 Data Could Trigger Domino Effect in Developing 4-1BB Candidates

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

03/09/2018

Company Report

Pages: 6

2017 Results; Marching Towards Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party